
Health Check: Neuren says more patients are staying the course as US Daybue sales lift
Neuren reports that more patients are staying the course with its Rett syndrome drug, Daybue. Pic via Getty Neuren says the number of patients discontinuing its Rett syndrome drug has fallen by two-thirds over the last year LTR Pharma launches a secondary …